The drawbacks of chemical CO2 absorbers include the production of compounds harmful to patients that also lead into increased cost and environmental impact, as well as the daily disposal of compound special waste. Sustainable management of general anesthesia is a growing concern. Continually diluting anesthetic circuits, and the disposal of chemical granulate are serious environmental problems.

DMF Medical has developed a next-generation CO2 filter in order to address the safety issues with current chemical CO2 absorbers in anesthesia.

memsorb uses patented advanced medical membrane technology to filter CO2 from anesthetic circuits rather than absorbing via a chemical reaction.

This game changing technology relies on a polymeric membrane core (similar to the ones used in oxygenators for cardiac surgery) that selectively allows CO2 to leave the rebreathing system, while maintaining the anesthetic vapor in the circuit.

memsorb is a cartridge similar in size and shape to current solutions that simply clicks in place.

Inclusion Criteria:

• American Society of Anesthesiologists Physical Status Class I, II, III (low-medium risk patient)
• English-speaking patients

Exclusion Criteria:

• Self-reported as pregnant
• American Society of Anesthesiologists Physical Status Class IV (high risk patient)
• Patients scheduled for emergency surgery
• Documented respiratory disease, including COPD and severe asthma
• Documented elevated pressure in the brain (intra cranial pressure, ICP)

Surgical patients

From the start to the end of the intra-operative period for each participant, an average of 1 hour.

The definitions of adverse event (AE) and serious adverse event (SAE) used in this study were consistent with the ClinicalTrials.gov definitions. AE data were collected only during the intra-operative period for each participant. No adverse events or serious adverse events were observed or reported during the study."

Early termination in McGill branch due to limited ability to recruit.